NASDAQ · SPRB
Spruce Biosciences, Inc.
$46.82-$0.17 (-0.36%)
Spruce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.71% below the high.
Loading market information…
NASDAQ · BEAT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
HeartBeam, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.53% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
HeartBeam, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.09. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow HeartBeam, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 13, 2025 |
| -$0.18-20.0% vs estimate |
| $0.00 |
| Q4 2024 | Mar 13, 2025 | -$0.18+5.26% vs estimate | $0.00 |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.19-11.76% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $2.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$46.82-$0.17 (-0.36%)
Spruce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.71% below the high.
$0.49-$0.05 (-9.43%)
Outlook Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.57% below the high.
$1.42$0.00 (0.0%)
Equillium, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.89% below the high.
$1.30+$0.05 (+4.0%)
OS Therapies Incorporated’s quoted price sits in the lower half of its reported 52-week range, 42.22% below the high.
$10.88+$0.08 (+0.69%)
MiNK Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.76% below the high.
$1.10+$0.04 (+3.77%)
Werewolf Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.78% below the high.
$1.57+$0.01 (+0.64%)
Spectral AI, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.14% below the high.
$1.75-$0.46 (-20.81%)
CervoMed Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.5% below the high.
